$INSM

Bonstein Sara sold $246K of INSM

Bonstein Sara (Chief Financial Officer) sold 2,404 shares of INSMED Inc (INSM) at $102.27 ($0.25M total) on 2026-06-03.

Original reporting
SEC EDGAR · Bonstein Sara
Published Jun 5, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INSM
Bearish
medium confidence
Mentioned
$INSM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMBearishLow
01

Why it matters

The disclosure may slightly affect short-term sentiment among traders tracking insider behavior, but it does not introduce new operational, clinical, or financial information.

02

Market read

A single insider sale at a known price provides a modest sentiment datapoint without a fundamental catalyst.

03

What to watch

The filing does not state reason for sale, whether options/RSUs were involved, or whether other insiders simultaneously bought/sold—so signal-to-noise is limited.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5; sale dated June 3.

Background

This is an SEC Form 4 insider transaction: INSMED CFO Sara Bonstein reported an open-market sale of 2,404 shares on June 3, filed June 5.

Company-level read

Ticker impact

$INSMBearishMedium confidence
Context

CFO Sara Bonstein sold $245.9K of INSM shares via an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and quickly absorbed.

Evidence & confidence

The filing provides a concrete ownership-change datapoint, but insider sales are often routine and the article lacks new company fundamentals or guidance.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale was not pre-arranged under a 10b5-1 plan, but insider sales can still reflect diversification, taxes, or personal liquidity needs rather than bearish fundamentals.

Key entities

  • INSMED Inc

    Company whose CFO disclosed an open-market sale of common stock on SEC Form 4.

  • Sara Bonstein

    Chief Financial Officer who sold 2,404 shares at $102.27/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$INSMMed

Brensocatib Launches in Japan for Non-CF Bronchiectasis

Insmed Inc. launched Brinsupri (brensocatib hydrate) in Japan for non-cystic fibrosis bronchiectasis, following approvals in the U.S. and Europe. The treatment, backed by clinical trial data, is the first of its kind in Japan. Insmed executives highlighted its potential to address unmet medical needs and improve patient outcomes.

$INSMHigh

Insmed launches bronchiectasis treatment in Japan

Insmed Incorporated (INSM) launched BRINSUPRI Tablets 25 mg in Japan for treating non-cystic fibrosis bronchiectasis in adults and pediatric patients 12+. The therapy, approved in August 2026, is the first of its kind in Japan. BRINSUPRI is also approved in the U.S. and EU for similar indications. Common side effects include rash, dry skin, and hypertension. Insmed is a biopharmaceutical company based in New Jersey.

$INSMMed

In Japan, patients can now get the only approved treatment for a lung disease that permanently widens airways.

Insmed Inc. announced that BRINSUPRI, the first approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is now available by prescription in Japan. BRINSUPRI is a once-daily oral therapy designed to reduce airway inflammation. The company highlighted the substantial disease burden of NCFB and the need for effective treatments. Insmed also provided details on the drug's safety profile and potential side effects, including dermatologic and gingival adverse reactions.

$INSMMedAI 8/10

Insmed launches four phase 3 trials for lung disease therapy

Insmed Inc. (INSM) launched four Phase 3 trials for its lung disease therapy, treprostinil palmitil. The PALM program includes studies for pulmonary arterial hypertension, pulmonary hypertension with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Three trials have started, with the fourth expected in early 2027. The therapy is not yet approved.